IRIS PILOT – Extended Pilot Study With a Retinal Implant System


Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.

Full Title of Study: “Extended Pilot Study to Evaluate Pattern Recognition With a Chronic Retinal Implant System”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2010

Detailed Description

The Retinal Implant System consists of three main components, the Retinal Stimulator, which is the component actually implanted into the eye, the visual interface, and the Pocket Processor The Retinal Stimulator will be implanted into the eye of a blind subject during a surgical operation. However, the external components are activated only during the test sessions under the control of the investigator team. In a first step of the investigation a software controlled system on a PC which is connected to the Pocket Processor via Ethernet interface, will generate the defined stimulation patterns (bars, crosses, cubes). During the test session, the blind subject is exposed to a series of these stimulation patterns and he / she has to describe the visual perceptions. Based on his descriptions and in an interactive way, the stimulation signal is subsequently be modulated by changing parameters like amplitude, duration of impulse, polarity, number of repetitions or pulse frequency on the PC. In a second step the visual interface is equipped with a camera which presents realtime images to the subject. Data obtained from the investigation with computer generated patterns in the first step are used in the second step to improve the fitting software for the use in the camera supported system. Finally the system should enable the subject to recognize simple images supported from the camera.


  • Device: Retinal Implant System (IRIS)
    • AIMD – Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina

Clinical Trial Outcome Measures

Primary Measures

  • Investigate whether blind subjects that fulfill the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.
    • Time Frame: 18 months

Secondary Measures

  • Secondary goals of this study phase are: Further evaluation of stimulation parameters, Light localization with use of camera, Safety verification of stimulation parameters
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age between 30 and 79 years at the date of enrollment – Normal hearing and linguistic understanding (with hearing aids if – necessary and in the language of the hospital or in English) – Ability to understand the study and procedures involved – Willingness to participate and comply with follow-up procedures – Good general health based on investigator's opinion – Ability to undergo surgery using general anaesthesia – Signed informed consent – RP, choroideremia, or rod cone dystrophy – Visual field less than 40 ° (if measurable) – Visual acuity not better than (1/50), (logMAR≥1.7) – Visual function stable for a duration of at least one year (according to subject statement) – Normal eye pressure (9-21 mmHg) – Bulbus length (AP) between 21 and 25 mm Exclusion Criteria – Allergic response to multiple antibiotics – Known allergies to materials of the implant – Known carrier of multi-resistant organisms – Pregnancy or lactating – History of epileptic seizures – Having active implantable devices (or need within the next 3 years) – Patients with cancer or patients received cancer therapy within the last 2 years – Currently undergoing psychiatric treatment without expert opinion approving participation on the study – Patients having insufficient mental capacity – Neurological diseases, in particular those affecting nerve conduction velocities – Patients currently taking medications affecting brain function – Immunosuppressive subjects

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Intelligent Medical Implants GmbH
  • Provider of Information About this Clinical Study
    • Intelligent Medical Implants GmbH, Medical device industry
  • Overall Official(s)
    • Gisbert Richard, Prof., Principal Investigator, Klinik und Poliklinik für Augenheilkunde Hamburg-Eppendorf


Hornig R, Laube T, Walter P, Velikay-Parel M, Bornfeld N, Feucht M, Akguel H, Rössler G, Alteheld N, Lütke Notarp D, Wyatt J, Richard G. A method and technical equipment for an acute human trial to evaluate retinal implant technology. J Neural Eng. 2005 Mar;2(1):S129-34. Epub 2005 Feb 22.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.